Ultherapy Prime Launch Update: What's Available in Korea Now

Three years on from Merz Aesthetics' first regional Prime previews, the Ultherapy Prime platform has finally settled into something close to standard in the higher-volume Gangnam clinics — but the picture on the ground is still uneven, and the numbers patients hear in consultation rooms tend to lag the marketing by twelve to eighteen months. I checked in with three Cheongdam-dong coordinators, read the Merz Asia-Pacific press deck from the 2023 launch event, and pulled the Korean MFDS device clearance record to figure out where Prime actually stands as of May 2026. This is the launch-and-adoption update I wish someone had handed me before my third trip — the timeline, the early adopters, the chains that were slow, and what the rollout looks like across Gangnam right now.

The Prime launch timeline, from Merz to Korea

Merz Aesthetics first announced the Prime platform internationally in late 2022, with the U.S. commercial launch and the FDA 510(k) clearance arriving in early 2023 under the Ulthera, Inc. submission record. The Korean rollout followed on a slightly different cadence — Merz Korea began running provider previews in the second half of 2023, and the formal Korean MFDS (Ministry of Food and Drug Safety) device clearance for the Prime hardware was secured by the end of 2023. Commercial sales into Korean clinics began in earnest in early 2024, which is the date most Gangnam coordinators will reference if you ask them when their clinic acquired the device.

That phasing is worth understanding because the Korean launch overlapped a competitive window in which several domestic MFU manufacturers — Classys with the Shurink Universe generation, Hironic with revised Doublo cartridges — were also pushing hardware refreshes. Merz Korea's launch strategy, in my reading of the press materials, leaned into the FDA-clearance differentiator and the throughput numbers (faster line delivery, redesigned transducer set) rather than competing head-on with the Korean platforms on cartridge price. Korean providers I spoke with described the early-2024 sales motion as Merz prioritizing higher-volume aesthetic clinics with established Ultherapy footprints — meaning the early Prime adopters were almost exclusively practices that were already running the original Ulthera and were trading up rather than buying into MFU for the first time.

A caveat on dates. Merz has not published a Korea-specific launch press release in the way some manufacturers do for individual market entries, and the timeline above is reconstructed from the Asia-Pacific press deck, the MFDS device portal, and provider interviews. If you see a clinic claiming Prime adoption before late 2023, ask which device they actually have on the floor — there were preview units running in a small number of Korean clinics during the 2023 Merz preview phase, but those were not yet commercial-sale units.

Which Gangnam clinic chains adopted Prime first

I want to be careful here, because Korean medical advertising rules (article 56 paragraph 4 of the Medical Service Act) prohibit comparative ranking of named medical institutions, and an editorial responsibility runs in the same direction. What I can say categorically, without naming any specific clinic, is that the early-adopter pattern in Gangnam was concentrated in three categories: the larger multi-floor aesthetic chains in Apgujeong and Cheongdam that already had a high-volume Ultherapy practice; the foreign-patient-focused clinics in Sinsa-dong and around Gangnam Station that lean on FDA-clearance marketing; and a smaller subset of single-physician practices run by Korean providers who had personal Merz training relationships. The pattern is not surprising — Prime cartridges run materially higher than the Korean MFU alternatives, and the clinics with the volume to absorb that cost structure were the ones that adopted earliest.

The slower adopters, in roughly the same Gangnam radius, were the budget-tier clinics that had built their MFU practices on Shurink Universe or Doublo Gold, the dermatology clinics that treated MFU as a smaller line item rather than a flagship offering, and the newer practices opened post-2022 that started with the lower-cost Korean platforms and have not yet seen a commercial reason to add Prime. Coordinators describe the budget-tier holdout pattern as economically rational rather than clinically driven — patients who walk into those clinics are usually optimizing for per-session cost rather than asking for Prime by name, and the platform-acquisition math hasn't justified the upgrade. That picture has begun shifting in 2026 as Prime adoption normalizes upward, but the gap remains real.

One practical note. The clinics that adopted Prime in the first wave (early-to-mid 2024) have now had eighteen-to-twenty-four months of operator time on the platform, which matters for the consistency-of-result conversation more than the device generation does. A Prime device installed in a clinic three months ago, with a provider running her first ten Prime sessions, will not produce the same reliability as the same provider on her original Ulthera with three years of muscle memory. Ask when the clinic acquired the Prime hardware, and how many Prime sessions the specific provider has performed on it. Both questions are legitimate, and both answers are usually given without hesitation by reputable practices.

What the 2026 adoption picture actually looks like

Across the three coordinators I checked in with for this update, the rough adoption read in the Apgujeong-Cheongdam-Sinsa corridor of Gangnam in May 2026 is roughly this: a clear majority of the higher-volume aesthetic clinics that previously ran original Ulthera have now upgraded to Prime, with a meaningful subset still keeping the original device on the menu for patients who request continuity with prior sessions; a smaller but growing share of mid-tier clinics have added Prime alongside their existing Korean MFU platform without retiring it; and the budget-tier and Korean-MFU-loyal clinics remain largely on Shurink Universe, Doublo Gold, or Ultraformer III without Prime in the room. None of those numbers are precise, and I would not put a percentage on any of them — the corridor is too dense and too rapidly shifting to support a reliable count without a survey effort I haven't done.

What I can say is that the Prime upgrade has reached the point of being the default expectation for U.S. patients walking into a higher-tier Gangnam consultation. Two years ago, asking about Prime would have surfaced a polite "the original device is what we use, results are comparable" answer in a meaningful share of clinics. Today, that answer is usually replaced with a confident "yes, we run Prime, would you like to see the device" — which is itself a marker of how broadly the platform has been absorbed. The patients still being routed to the original device are the ones who specifically prefer it for continuity reasons or who are working from a price-sensitive package the clinic offers as a budget alternative.

A second adoption signal worth flagging. The Korean MFU manufacturers — Classys most visibly — have responded to Prime's positioning with refreshed cartridge sets and updated marketing language emphasizing throughput and operator workflow. That response is the kind of competitive pressure that tends to compress the price gap on both sides, and Gangnam coordinators describe the pricing landscape in 2026 as more compressed than it was in 2023. Prime's premium over Shurink Universe at matched line counts is now smaller than it was at launch, partly because Prime cartridge availability has improved and partly because the Korean alternatives have not held their pre-Prime price floor. None of this is a clinical argument. It is a market-pressure read. But it explains why Prime now appears on more pricing sheets than the early-adopter pattern alone would predict.

Comparison: original Ulthera availability versus Prime in Gangnam, 2026

For patients trying to decide whether to look for original Ulthera specifically or to default to Prime, the rough availability matrix below is the snapshot I've been using on this trip. Read it as descriptive — a categorical guide to where each device generation fits in a 2026 Gangnam consultation, not a recommendation. The right device depends on your indication, the practitioner's case volume, and your tolerance for the price step.

What this means for patients booking in 2026

The practical patient takeaway, in my reading, is that Prime is now widely enough available in Gangnam that you do not need to filter your clinic shortlist around it. Most higher-volume practices you'd consider on other criteria (provider experience, language support, distance from your hotel) will have Prime on the menu, often alongside the original device for patients who want continuity. The exception is the budget-tier and Korean-MFU-loyal segment, where Prime is still uncommon and the clinic will usually be transparent about that during consultation rather than upselling toward an absent device.

If Prime is specifically what you want, my honest read is to confirm three things during the consultation. First, that the clinic has the Prime device on the floor and will use it for your session — "yes, we run Prime" sometimes means "we have access to a Prime device through a partner clinic" rather than "we own and operate one in our suite." Second, the specific provider's case volume on Prime — twelve to twenty-four months of platform time tends to be the threshold where operator hand stabilizes. Third, which transducer set will be used, since some clinics adopted Prime hardware without acquiring the full body-transducer expansion, and the platform's body-treatment capability depends on those specific cartridges.

For patients who don't have a strong preference between Prime and the original device, the honest answer is that the result delta is modest in skilled hands — and the experienced operator on a familiar device produces a more reliable outcome than the same operator on a newer device with less floor time. Don't let the marketing reframe the question. The platform helps; it doesn't carry the result. Patients report that the bigger drivers of session quality remain provider experience, line plan, and realistic expectation-setting, regardless of which generation of the Merz hardware is in the room. The launch update changes the availability picture in Gangnam. It does not change the questions worth asking.

Caveats, conflict-of-interest disclosure, and what to watch

A few honest caveats. The adoption read above is reconstructed from three coordinator conversations and the Merz Asia-Pacific press deck, not a clinic-by-clinic survey, and the Gangnam corridor is dense enough that a clinic-level census would require an effort I haven't undertaken for this piece. The MFDS device portal lists the Prime hardware clearance under the Ulthera, Inc. submission record, which patients can verify directly via the MFDS English portal. The U.S. FDA 510(k) clearance for the Prime platform is similarly verifiable on the FDA medical device database. I encourage you to check both yourself if the regulatory paper trail matters to your decision.

No conflict of interest to disclose on the device or manufacturer side — I do not have a Merz relationship, a Classys relationship, or a stake in any specific clinic. What I do have is multiple personal Ultherapy sessions across both device generations, which colors my read of the platform and the experience even if it does not bias the launch-and-adoption summary itself. Studies suggest the broader MFU mechanism is well-supported across platforms; the launch update above is about availability and adoption, not relative clinical superiority. May help is the right framing for any device-specific claim — and I default to it deliberately.

What to watch in the next twelve months. Merz has previewed an updated transducer line for the Prime platform that targets specific facial sub-zones, which has not yet reached widespread Korean adoption as of May 2026. The pricing pressure from the refreshed Korean MFU platforms (Classys's Shurink Universe revisions, the newer V-RO entrant) has begun compressing Prime's premium and may continue to do so. And the maintenance-tier MFU category — gentler, shorter sessions for returning patients — is growing fast enough in Gangnam that the conversation about how Prime fits into a multi-year regimen, rather than as a standalone choice, is becoming the more useful frame. I'll plan to update this piece around the next Merz Asia-Pacific press cycle, which historically lands in the second half of the calendar year.

Frequently asked questions

When did Ultherapy Prime actually launch in Korea?

Korean MFDS device clearance for the Prime platform was secured by the end of 2023, with commercial sales into Korean clinics beginning in earnest in early 2024. Merz Korea ran provider previews during the second half of 2023, which is why some clinics describe themselves as having early access — those were preview units rather than commercial-sale installations. If a clinic claims Prime adoption before late 2023, ask which device they actually have on the floor.

Is Ultherapy Prime FDA-cleared and KFDA-cleared?

Yes to both. The U.S. FDA 510(k) clearance was secured in early 2023 under the Ulthera, Inc. submission record, with the same indications as the original Ulthera (brow lift, submentum, neck, décolletage). The Korean MFDS clearance followed in late 2023. Both regulatory records are publicly verifiable — the FDA via the medical device database and MFDS via its English-language device portal. Patients who want to confirm the paper trail can do so in five minutes.

Do most Gangnam clinics actually have Prime in 2026, or is it still concentrated in early adopters?

A clear majority of higher-volume Gangnam aesthetic clinics that previously ran original Ulthera have upgraded to Prime by 2026, with the first wave landing in early 2024. Mid-tier clinics have been adopting at a slower pace through 2025 and into 2026. The budget-tier and Korean-MFU-loyal segments are still largely on Shurink Universe, Doublo Gold, or Ultraformer without Prime in the room — and that picture is unlikely to shift quickly until the price gap compresses further.

If a clinic says they have Prime, what should I confirm during consultation?

Three things. One, that the device is physically on the clinic floor and will be used for your session — not accessed through a partner clinic. Two, the specific provider's case volume on Prime over the last twelve to twenty-four months. Three, which transducer set is available, since some clinics adopted the Prime hardware without acquiring the full body-treatment cartridge expansion. All three questions are routine, and reputable clinics answer them quickly.

Has the Prime launch made the original Ultherapy harder to find in Korea?

Not meaningfully. Most Gangnam clinics that upgraded to Prime have kept the original device on the menu, often as a continuity option for returning patients or as a slightly lower-priced alternative within the Merz line. Cartridge availability for the original platform remains stable in 2026, and patients who specifically want continuity with prior sessions on the original Ulthera will usually find that option without difficulty. The platform is older, not retired.

Has the Prime price premium changed since the 2024 Korean launch?

It has narrowed. Prime's premium over the Korean MFU alternatives at matched line counts is smaller in 2026 than it was at launch, partly because cartridge availability has improved and partly because the Korean platforms (Shurink Universe revisions, V-RO entrant) have applied competitive pressure on the broader MFU pricing landscape. Coordinators describe the 2026 pricing as more compressed than 2023. The exact step varies by clinic, but the headline gap is smaller than the early launch period suggested.